Renaissance Technologies LLC Buys 68,100 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Renaissance Technologies LLC lifted its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 106.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 131,899 shares of the company’s stock after purchasing an additional 68,100 shares during the quarter. Renaissance Technologies LLC’s holdings in TransMedics Group were worth $19,867,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Goldman Sachs Group Inc. grew its stake in shares of TransMedics Group by 10.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 397,283 shares of the company’s stock worth $31,358,000 after buying an additional 38,951 shares during the last quarter. Vanguard Group Inc. grew its position in TransMedics Group by 2.8% during the 4th quarter. Vanguard Group Inc. now owns 1,865,115 shares of the company’s stock worth $147,214,000 after acquiring an additional 50,673 shares during the last quarter. Alpha DNA Investment Management LLC acquired a new position in TransMedics Group in the 4th quarter worth about $500,000. Russell Investments Group Ltd. raised its position in TransMedics Group by 337,462.5% in the first quarter. Russell Investments Group Ltd. now owns 27,005 shares of the company’s stock valued at $1,997,000 after purchasing an additional 26,997 shares during the last quarter. Finally, Hsbc Holdings PLC boosted its stake in shares of TransMedics Group by 19.0% during the fourth quarter. Hsbc Holdings PLC now owns 41,650 shares of the company’s stock valued at $3,287,000 after purchasing an additional 6,650 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

TMDX has been the topic of several recent research reports. Oppenheimer lifted their target price on shares of TransMedics Group from $125.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday, August 1st. Piper Sandler boosted their price objective on shares of TransMedics Group from $170.00 to $180.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st. Morgan Stanley raised their target price on TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. TD Cowen upped their price target on TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a research report on Friday, June 7th. Finally, Stephens raised their price objective on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, TransMedics Group has an average rating of “Moderate Buy” and a consensus price target of $171.44.

TransMedics Group Stock Performance

Shares of TransMedics Group stock opened at $165.00 on Friday. The business has a 50-day moving average price of $155.65 and a two-hundred day moving average price of $128.98. TransMedics Group, Inc. has a 1-year low of $36.42 and a 1-year high of $177.37. The company has a current ratio of 9.37, a quick ratio of 8.48 and a debt-to-equity ratio of 2.67. The company has a market cap of $5.43 billion, a P/E ratio of -485.29 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Wednesday, July 31st. The company reported $0.35 EPS for the quarter, topping the consensus estimate of $0.21 by $0.14. The business had revenue of $114.30 million during the quarter, compared to analysts’ expectations of $98.84 million. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The firm’s revenue was up 117.7% on a year-over-year basis. During the same quarter last year, the firm posted ($0.03) earnings per share. As a group, analysts anticipate that TransMedics Group, Inc. will post 1.23 EPS for the current year.

Insider Transactions at TransMedics Group

In related news, insider Tamer I. Khayal sold 2,958 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $156.77, for a total transaction of $463,725.66. Following the transaction, the insider now directly owns 20,843 shares of the company’s stock, valued at $3,267,557.11. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, insider Tamer I. Khayal sold 2,958 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $156.77, for a total transaction of $463,725.66. Following the transaction, the insider now directly owns 20,843 shares of the company’s stock, valued at approximately $3,267,557.11. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $145.17, for a total value of $1,252,091.25. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $8,948,714.31. The disclosure for this sale can be found here. Insiders sold a total of 61,247 shares of company stock valued at $9,650,880 in the last quarter. 7.00% of the stock is currently owned by company insiders.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.